What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, <i>BRCA</i>, <i>PTEN</i>, and Other Genes

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, <i>BRCA</i>, <i>PTEN</i>, and Other Genes

Pembrolizumab (anti-PD-1) is allowed in selected metastatic castration-resistant prostate cancer (PC) patients showing microsatellite instability/mismatch repair system deficiency (MSI-H/dMMR). <i>BRCA1/2</i> loss-of-function is linked to hereditary PCs and homologous recombination DNA-r...

Full description

Bibliographic Details
Main Authors: Andrea Palicelli, Stefania Croci, Alessandra Bisagni, Eleonora Zanetti, Dario De Biase, Beatrice Melli, Francesca Sanguedolce, Moira Ragazzi, Magda Zanelli, Alcides Chaux, Sofia Cañete-Portillo, Maria Paola Bonasoni, Stefano Ascani, Antonio De Leo, Guido Giordano, Matteo Landriscina, Giuseppe Carrieri, Luigi Cormio, Jatin Gandhi, Davide Nicoli, Enrico Farnetti, Simonetta Piana, Alessandro Tafuni, Martina Bonacini
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Biomedicines
Subjects:
PD-L1
prostate
cancer
<i>BRCA</i>
mismatch repair
microsatellite instability
Online Access:https://www.mdpi.com/2227-9059/10/2/236

Internet

https://www.mdpi.com/2227-9059/10/2/236

Similar Items